DC
INO icon

Diametric Capital’s Inovio Pharmaceuticals INO Stock Holding History

Diametric Capital’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,491
Closed -$42.6K – 575
2026
Q1 		$42.6K Buy
+24,491
New +$40.3K 0.01% 456
2022
Q3 		– Sell
-1,287
Closed -$27K – 289
2022
Q2 		$27K Buy
+1,287
New +$36.3K 0.02% 245

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Diametric Capital's INO Position: Q2 2026 in Review

Diametric Capital sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 24,491 shares — an estimated $42.6K sold.

Diametric Capital first reported a position in INO in Q2 2022 and held it in 2 quarters. The position peaked at $42.6K in Q1 2026. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Diametric Capital reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 24,491 Inovio Pharmaceuticals shares in Q2 2026, an estimated $42.6K.
  • Diametric Capital first reported a position in Inovio Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Diametric Capital's Inovio Pharmaceuticals position peaked at $42.6K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.